The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Abstract
Tumorigenesis is associated with enhanced cellular glucose uptake and increased metabolism. Because the p53 tumor suppressor is mutated in a large number of cancers, we evaluated whether p53 regulates expression of the GLUT1 and GLUT4 glucose transporter genes. Transient cotransfection of osteosarcoma-derived SaOS-2 cells, rhabdomyosarcoma-derived RD cells, and C2C12 myotubes with GLUT1-P-Luc or GLUT4-P-Luc promoter-reporter constructs and wild-type p53 expression vectors dose dependently decreased both GLUT1 and GLUT4 promoter activity to approximately 50% of their basal levels. PG13-Luc activity, which was used as a positive control for functional p53 expression, was increased up to ∼250-fold by coexpression of wild-type p53. The inhibitory effect of wild-type p53 was greatly reduced or abolished when cells were transfected with p53 with mutations in amino acids 143, 248, or 273. A region spanning −66/+163 bp of the GLUT4 promoter was both necessary and sufficient to mediate the inhibitory effects of p53. Furthermore, in vitro translated p53 protein was found to bind directly to two sequences in that region. p53-DNA binding was completely abolished by excess unlabeled probe but not by nonspecific DNA and was super-shifted by the addition of an anti-p53 antibody. Taken together, our data strongly suggest that wild-type p53 represses GLUT1 and GLUT4 gene transcription in a tissue-specific manner. Mutations within the DNA-binding domain of p53, which are usually associated with malignancy, were found to impair the repressive effect of p53 on transcriptional activity of the GLUT1 and GLUT4 gene promoters, thereby resulting in increased glucose metabolism and cell energy supply. This, in turn, would be predicted to facilitate tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53 regulates glucose transporters (GLUTs) that promote glucose transport across the cellular plasma membrane to inhibit glucose uptake.84,85”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [84]
In the citing paper
“p53 inhibits glucose uptake and glycolysis by suppressing the expression and translocation of glucose transporter proteins such as GLUT1 and GLUT4.97”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Over the past several years, the p53 tumor suppressor protein has emerged as one of the most important cellular factors for preserving the integrity of the genome (4, 5 ). The p53 protein is a tetrameric phosphoprotein that mediates signal transduction from damaged DNA to genes involved in regulation of the cell cycle…”
BackgroundDefinition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Over-expression of facilitative glucose transporter genes in human cancer
Yamamoto, T., Seino, Y., Fukumoto, H., Koh, G., Yano, H., Inagaki, N., Yamada, Y., Inoue, K., Manabe, T., & Imura, H. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91263-r · Cited by 465
Yamaguchi, A., Tamatani, M., Matsuzaki, H., Namikawa, K., Kiyama, H., Vitek, M. P., Mitsuda, N., & Tohyama, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008552200 · Cited by 242
p53 Suppresses the Activation of the Bcl-2 Promoter by the Brn-3a POU Family Transcription Factor
Budhram-Mahadeo, V., Morris, P. J., Smith, M. D., Midgley, C. A., Boxer, L. M., & Latchman, D. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15237 · Cited by 144
Research works printed but not linked: 34
- Hollingsworth RE, Lee WH Tumor suppressor genes: new prospects for cancer research. J Natl Cancer Inst (Bethesda), 83: 91-6, 1991. · DOI
- Hatanaka M Transport of sugars in tumor cell membranes. Biochim Biophys Acta, 355: 77-104, 1974. · DOI · Paper page
- Flier JS, Mueckler MM, Usher P, Lodish HF Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science, 235: 1492-5, 1987. · DOI · Paper page
- Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, et al Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol, 64: 865-71, 2002. · DOI
- Oren M Regulation of the p53 tumor suppressor protein. J Biol Chem, 274: 36031-4, 1999. · DOI · Paper page
- Lane DP, Lain S Therapeutic exploitation of the p53 pathway. Trends Mol Med, 8: S38-42, 2002. · DOI
- Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P New approaches to understanding p53 gene tumor mutation spectra. Mutat Res, 431: 199-209, 1999. · DOI · Paper page
- Kahn BB Facilitative glucose transporters: regulatory mechanisms and dysregulation in diabetes. J Clin Investig, 89: 1367-74, 1992. · DOI · Paper page
- MacDougald OA, Lane MD Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem, 64: 345-73, 1995. · DOI · Paper page
- Maor G, Karnieli E The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology, 140: 1841-51, 1999. · doi:10.1210/endo.140.4.6620
- Werner H, Hernandez-Sanchez C, Karnieli E, Leroith D The regulation of IGF-I receptor gene expression. Int J Biochem Cell Biol, 27: 987-94, 1995. · doi:10.1016/1357-2725(95)00074-y
- Haber RS, Weiser KR, Pritsker A, Reder I, Burstein DE GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid, 7: 363-7, 1997. · DOI
- Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res, 90: 1238-43, 1999. · DOI
- Medina RA, Owen GI Glucose transporters: expression, regulation and cancer. Biol Res, 35: 9-26, 2002. · DOI · Paper page
- Nagamatsu S, Sawa H, Wakizaka A, Hoshino T Expression of facilitative glucose transporter isoforms in human brain tumors. J Neurochem, 61: 2048-53, 1993. · DOI
- Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, et al PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro. J Clin Endocrinol Metab, 87: 5312-24, 2002. · DOI
- Berlangieri SU, Scott AM Metabolic staging of lung cancer. N Engl J Med, 343: 290-2, 2000. · doi:10.1056/nejm200007273430410
- Werner H, Karnieli E, Rauscher FJ, LeRoith D Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA, 93: 8318-23, 1996. · DOI · Paper page
- Fogh J, Wright WC, Loveless JD Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst (Bethesda), 58: 209-14, 1977. · DOI · Paper page
- Quon MJ, Zarnowski MJ, Guerre-Millo M, de la Luz Sierra M, Taylor SI, Cushman SW Transfection of DNA into isolated rat adipose cells by electroporation: evaluation of promoter activity in transfected adipose cells which are highly responsive to insulin after one day in culture. Biochem Biophys Res Commun, 194: 338-46, 1993. · DOI
- Armoni M, Kritz N, Harel C, Bar-Yoseph F, Quon MJ, Karnieli E Peroxisome proliferator-activated receptor γ represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem, 278: 30614-23, 2003. · DOI
- Lee Y, Chen Y, Chang LS, Johnson LF Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res, 234: 270-6, 1997. · DOI
- Sambrook J . Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY 1989.
- Zambetti G, Levine A A comparison of the biological activities of wild-type and mutant p53. FASEB J, 7: 855-65, 1993. · DOI · Paper page
- Blagosklonny M Loss of function and p53 protein stabilization. Oncogene, 15: 1889-93, 1997. · doi:10.1038/sj.onc.1201374
- Shiio Y, Yamamoto T, Yamaguchi N Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA, 89: 5206-10, 1992. · DOI
- Wang Q, Zambetti G, Suttle D Inhibition of DNA topoisomerase II α gene expression by the p53 tumor suppressor. Mol Cell Biol, 17: 389-97, 1997. · DOI
- Seto E, Usheva A, Zambetti G, Momand J, Horikoshi N, Weinmann R, et al Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA, 89: 12020-32, 1992. · DOI · Paper page
- Liu X, Berk A Reversal of in vitro p53 squelching by both TFIIB and TFIID. Mol Cell Biol, 15: 6474-8, 1995. · DOI
- Horikoshi N, Usheva A, Chen J, Levine A, Weinmann R, Shenk T Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol, 15: 227-34, 1995. · DOI · Paper page
- Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al Molecular biology of mammalian glucose transporters. Diabetes Care, 13: 198-208, 1990. · DOI · Paper page
- Lee KC, Crowe AJ, Barton MC p53-mediated repression of α-fetoprotein gene expression by specific DNA binding. Mol Cell Biol, 19: 1279-88, 1999. · DOI · Paper page
- Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J, 17: 544-53, 1998. · DOI
- Johnson RA, Ince TA, Scotto KW Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem, 276: 27716-20, 2001. · DOI
Cited by
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Metadata
- Authors
- Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E.
- Venue
- Cancer Research
- Published
- 2004-04-01
- Volume
- 64
- Issue
- 7
- Pages
- 2627-2633
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2035608099
- Cited by
- 726
- References
- 5
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-0846
- The paper
- Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004). The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-0846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.